ThromboGenics, Flanders Institute for Biotechnology (VIB), Oncurious deal

ThromboGenics and VIB launched Oncurious, a new company with worldwide, co-development rights to TB-403 for oncology. ThromboGenics will hold more than 90% of the newco, and VIB will own the remainder. Oncurious and co-development partner BioInvent International AB (SSE:BINV, Lund, Sweden) plan to begin a Phase I/IIa trial of TB-403 to treat medulloblastoma by year-end. The partners declined to disclose financial terms. ...